TRISOL MEDICAL LTD

Their core work

Trisol Medical is an Israeli medical device company developing a catheter-delivered prosthetic heart valve specifically designed to replace damaged tricuspid valves — the right-side heart valves long overlooked by the surgical implant industry. Their core product, the TriSol System, addresses severe Tricuspid Regurgitation (TR), a condition where the tricuspid valve fails to close properly, causing blood to flow backward and progressively damaging the right ventricle. The company progressed through the full EU SME Instrument pathway, moving from feasibility validation in 2018 to a multi-year clinical-stage development project running through 2024, indicating they are at an advanced product development stage. Their value lies in a combination of novel valve prosthesis design and a purpose-built delivery system — a complete solution, not just a device.

What they specialise in

How they've shifted over time

Trisol Medical's H2020 trajectory follows a clean, linear product development arc rather than a shifting research focus. Their 2018 Phase 1 project was a lean feasibility study (€50K) with no published keywords, consistent with early-stage concept validation under commercial confidentiality. By the time their Phase 2 project launched in 2020, their terminology crystallized around five precise clinical and engineering terms — tricuspid regurgitation, heart replacement valve, right ventricular dysfunction, delivery system, and heart valve surgery — signaling a shift from exploration to execution. There is no pivot or topic drift; this is a single-product company deepening its commitment to one well-defined clinical problem.

Trisol is on a single-track trajectory toward commercializing the TriSol System for tricuspid regurgitation; future collaboration interest likely centers on clinical validation, regulatory affairs, and hospital network access in Europe.

How they like to work

Trisol has acted exclusively as coordinator in both of its EU projects, which is characteristic of SME Instrument awards — that funding scheme is designed for single-company innovation, not consortia. As a result, they show zero recorded consortium partners across their entire H2020 history, meaning their EU collaboration profile is that of a self-directed innovator rather than a network builder. Anyone approaching Trisol for partnership should expect to engage a focused, commercially-driven team rather than an organization experienced in multi-partner project governance.

Trisol's H2020 record shows no consortium partners — both grants were awarded directly to the company as sole beneficiary under the SME Instrument scheme. Their formal EU research network is therefore limited to their bilateral relationship with the European Commission as funder, with no documented cross-border research collaborations on record.

What sets them apart

Trisol Medical occupies a narrow but commercially significant niche: transcatheter tricuspid valve replacement, a segment that received far less industry investment than aortic or mitral valve interventions until recently, creating a window for specialized SMEs. Based in Yokneam — Israel's medical device cluster — they operate within a strong national ecosystem for cardiovascular device development and have secured EU funding despite not being an EU member state, reflecting the scientific credibility of their approach. For consortium builders seeking a cardiovascular device partner with both a defined product and regulatory-track experience, Trisol offers focused depth rather than broad research breadth.

Highlights from their portfolio

• Trisol System (Phase 2)
  At €2.32M, this is one of the larger SME Instrument Phase 2 awards and represents a 46-fold funding increase from Phase 1, indicating strong EU evaluator confidence in the technology and commercial case.
• TriSol System (Phase 1)
  The successful Phase 1 feasibility award in 2018 served as the gateway grant that validated Trisol's concept and unlocked the much larger Phase 2 development investment.